Bio-Thera Solutions: all 57 studies

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular EdemaRecruitingNCT07515079Phase 3
• A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental GlomerulosclerosisRecruitingNCT07499700Phase 2/3
• BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical CancerRecruitingNCT06123884Phase 2/3
• Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for InjectionRecruitingNCT05620017Phase 1
• A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung CancerCompletedNCT03329911Phase 3Results posted
• A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer ParticipantsActive, not recruitingNCT07180862Phase 1
• A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian CancerWithdrawnNCT06545617Phase 1/2
• A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic TumorsActive, not recruitingNCT06376136Phase 1/2
• A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid TumorsActive, not recruitingNCT06341114Phase 1/2
• BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial CancerTerminatedNCT06321068Phase 2/3
• A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLCTerminatedNCT06280196Phase 3
• Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors PatientsCompletedNCT06139536Phase 1
• Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male SubjectsCompletedNCT06111196Phase 1
• Evaluate the Safety, Tolerability of BAT6026Active, not recruitingNCT06094179Phase 1/2
• A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT06044350Phase 2
• A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male SubjectsCompletedNCT05968508Phase 1
• To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid TumorsTerminatedNCT05879627Phase 1
• A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 InjectionCompletedNCT05865574Phase 1
• Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors PatientsCompletedNCT05848466Phase 1
• Clinical Study of Stage IV Psoriasis in Children With GeleliCompletedNCT05803187
• BAT7104 Injection in Patients With Advanced Malignant Tumors.CompletedNCT05767060Phase 1
• Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male SubjectsCompletedNCT05576454Phase 1
• Evaluate the Pharmacokinetics of BAT2022 in Healthy Chinese SubjectsCompletedNCT05518695Phase 1
• Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular DegenerationCompletedNCT05439629Phase 3
• Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006CompletedNCT05414136Phase 1
• Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009Status unknownNCT05405621Phase 1
• Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for InjectionCompletedNCT05378737Phase 1
• Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis PatientsCompletedNCT05377944Phase 3
• A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®CompletedNCT05332730Phase 1
• BAT7104 in Patients With Advanced Solid TumoursCompletedNCT05200013Phase 1
• Assessment of Safety , Clinical Efficacy With QLETLI in Non-infectious Uveitis (UV)CompletedNCT05180526Phase 4
• Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid TumorsCompletedNCT05155722Phase 1
• Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid TumorsCompletedNCT05148325Phase 1
• Clinical Study on the Efficacy and Safety of BAT5906 InjectionCompletedNCT05141994Phase 2
• Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in ChinaTerminatedNCT05120375Phase 1
• Assessment of Safety and Preliminary Clinical Efficacy with BAT6005 in Advanced Malignant Solid TumorsCompletedNCT05116709Phase 1
• Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour PatientsTerminatedNCT05109650Phase 1
• Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in ChinaCompletedNCT05105971Phase 1
• Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor PatientsTerminatedNCT05073484Phase 1
• Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic ArthritisCompletedNCT05046431Phase 3
• Study of Two Multiple Intravitreal Doses of BAT5906 for Safety and Efficacy in Patients With Diabetic Macular EdemaCompletedNCT04772105Phase 1/2
• Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT04728360Phase 3
• Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy SubjectsCompletedNCT04711343Phase 1
• A Phase 1/2 Study to Assess Safety and Efficacy of BAT2020 in Hospitalized COVID-19 PatientsWithdrawnNCT04432766Phase 1/2
• Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy SubjectsCompletedNCT04371185Phase 1
• A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for PatientsStatus unknownNCT04189211Phase 1
• The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast CancerStatus unknownNCT04185649Phase 3
• Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy SubjectsCompletedNCT04152759Phase 1
• A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for PatientsCompletedNCT04152148Phase 1
• A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With Solid TumorStatus unknownNCT04151329Phase 1/2
• A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular DegenerationCompletedNCT04151212Phase 1
• A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersCompletedNCT04146285Phase 1
• A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and HumiraCompletedNCT04135508Phase 3
• Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial CancerTerminatedNCT03884517Phase 1
• Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to MethotrexateCompletedNCT03830203Phase 3
• Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy SubjectsCompletedNCT03606876Phase 1
• Study of Bevacizumab(BAT1706) and Comparators in Healthy SubjectsCompletedNCT03030430Phase 1

← Bio-Thera Solutions overview and focus areas